This article examines emergency valve-in-valve transcatheter aortic valve implantation, a minimally invasive intervention for patients requiring urgent aortic valve replacement. The procedure represents an advanced therapeutic approach for managing acute aortic valve dysfunction, particularly in high-risk surgical candidates. By deploying a prosthetic valve within a previously implanted or diseased native valve, clinicians can address life-threatening cardiac conditions while minimizing procedural trauma. The emergency application highlights the technique's versatility and potential to improve patient outcomes in critical situations where traditional surgical intervention may pose excessive risk or prove logistically unfeasible.

This case study documents the successful management of acute thrombosis in an Edwards SAPIEN M3 transcatheter mitral valve replacement (TMVR) caused by oral anticoagulation nonadherence. A 58-year-old patient developed cardiogenic shock with severe mitral stenosis due to prosthetic valve thrombosis and heavy clot burden. Despite initial thrombolytic therapy, hemodynamic deterioration necessitated emergent valve-in-valve intervention, during which a 29-mm Edwards SAPIEN S3 Ultra Resilia valve was successfully implanted within the M3 valve. This rare but serious complication highlights the critical importance of strict anticoagulation adherence in TMVR patients. The case demonstrates that valve-in-valve reintervention represents an effective treatment option for high-risk surgical patients presenting with acute prosthetic valve thrombosis, underscoring the need for vigilant monitoring and early diagnostic consideration in transcatheter mitral valve systems.

Dr. Ehtisham Mahmud from UC San Diego Health discusses how robotic cath lab systems, particularly Corindus/Siemens Healthineers' Corpath GRX, could revolutionize emergency stroke care by enabling remote telemedicine procedures. This technology allows interventionalists to perform thrombectomy procedures from considerable distances, potentially transforming acute stroke treatment in underserved rural areas. Drawing parallels to the evolution of cardiac intervention standards over the past four decades, Mahmud notes that acute stroke care follows a similar trajectory but faces a critical shortage of neuro-interventional specialists. The robotic system could bridge this gap by allowing experienced cardiologists to remotely conduct procedures, though additional training in neuro-vascular techniques would be required. This innovation promises to significantly reduce healthcare disparities and improve access to emergency stroke interventions nationwide.

Tricuspid valve disease remains significantly undertreated despite substantial associated morbidity and mortality. Isolated medical management of severe tricuspid regurgitation carries approximately 40% one-year mortality, while traditional surgical approaches demonstrate in-hospital mortality rates of 10-12%. Late clinical diagnosis and heterogeneous patient populations complicate management. Recent advances in transcatheter interventions, including edge-to-edge repair and valve replacement techniques, have expanded treatment options and improved outcomes. Contemporary guidelines from the European Society of Cardiology and European Association for Cardio-Thoracic Surgery now recommend surgical correction during concurrent left-sided procedures and transcatheter therapy for symptomatic high-risk patients. Multidisciplinary heart team collaboration and refined risk stratification tools like the Tricuspid Regurgitation Impact Surgical Score enhance patient selection and decision-making, establishing new standards for tricuspid valve disease management.

This research examines age-related variations in mitral valve annulus morphology and their clinical implications. The study investigates how structural changes in the mitral valve annulus occur throughout the lifespan and how these alterations may affect valve function and disease susceptibility. Understanding these age-dependent anatomical variations is essential for accurate diagnosis and management of mitral valve pathology across different patient populations. The findings provide valuable insights into the relationship between aging processes and mitral valve anatomy, which has significant implications for cardiac imaging interpretation, surgical planning, and the development of age-appropriate clinical guidelines for mitral valve disease.

Mitral valve replacement and repair represent a rapidly evolving field in interventional cardiology, building on established experience with transcatheter aortic valve interventions. This comprehensive domain encompasses diverse innovative techniques and devices, with certain mitral repair solutions achieving widespread clinical adoption. Mastery of this complex specialty requires proficiency across multiple disciplines, including advanced imaging modalities such as echocardiography, vascular access strategies, emerging device technologies, pharmacological support, hemorrhage risk assessment, and sophisticated patient selection criteria. EuroIntervention serves as a leading reference journal dedicated to advancing knowledge in coronary, valvular, and structural interventions, providing clinicians with essential insights into the latest research and clinical developments shaping modern interventional practice.

The Mosaic Neo™ mitral bioprosthesis represents a next-generation native porcine valve designed for mitral valve replacement by Medtronic. Its innovative atrialized design reduces stent post protrusion by up to 23% compared to the legacy Mosaic™ valve, while strategically positioned cuff markings optimize leaflet orientation to preserve left ventricular outflow tract clearance. The wider interstrut distance at the anterior annulus minimizes obstruction risk. Long-term clinical evidence demonstrates superior durability compared to bovine pericardial alternatives, with significantly extended intervals before reoperation for structural valve deterioration. The platform incorporates enhanced procedural features including intuitive cuff markings, pre-attached barrel sizers, and a quick-detach handle system designed to streamline implantation and improve surgical workflow efficiency.

Effective management of primary mitral regurgitation demands a comprehensive lifetime strategy integrating both surgical and transcatheter interventions. Contemporary practice emphasizes early intervention timing, repair durability, and strategic planning for potential future reinterventions. A multidisciplinary Heart Team approach is essential to design the initial procedure while preserving therapeutic flexibility across the patient's lifespan. The recently updated 2025 ESC/EACTS Valvular Heart Disease Guidelines provide refined indications for early surgery, improved patient selection criteria for transcatheter edge-to-edge repair, and expanded recommendations for prosthetic valve failure management. This framework enables clinicians to pursue durable surgical repair as the primary goal while maintaining accessible options for subsequent interventions, ensuring optimal long-term outcomes for patients requiring mitral valve intervention.

Transcatheter tricuspid valve interventions have evolved significantly through early clinical experience and iterative refinement. The Cardioband system's early adoption highlighted critical challenges in direct annuloplasty, including technical complexity, imaging limitations, and anchor instability despite sound physiological principles. These lessons revealed that annular dilatation remains the primary driver of secondary tricuspid regurgitation, emphasizing the continued importance of annuloplasty as a therapeutic strategy. Future device development must address engineering constraints and workflow optimization to achieve reproducible, scalable interventions that build upon the foundation established by pioneering experiences.

Boston Scientific seeks an experienced Interventional Cardiologist for the Global Medical Director position in Maple Grove, Minnesota. This hybrid role offers physician leadership within the Global Cardiology Group, requiring presence in the office at least three times weekly. The successful candidate will provide medical expertise and strategic guidance across coronary, structural heart, and renal denervation technologies, serving as the clinical voice throughout the product lifecycle. Responsibilities include partnering with Clinical, R&D, Quality, Regulatory Affairs, and Commercial teams to advance clinical evidence generation, product development, and medical strategy. The position offers an opportunity to influence cardiovascular care advancement while supporting patient safety and therapeutic innovation globally. Boston Scientific provides comprehensive professional development, diverse team environments, and recognized workplace culture benefits. No visa sponsorship is available.

Integrating human factors into post-market surveillance represents a critical evolution in medical device safety management. While premarket usability studies establish baseline performance, real-world use generates insights that traditional surveillance mechanisms often miss. Both EU MDR and FDA regulations increasingly emphasize continuous demonstration of device usability and safety throughout product lifecycles. By incorporating human factors methodology into post-market surveillance activities, manufacturers can identify user interaction issues, understand root causes of problems, and proactively address safety risks. This integration strengthens regulatory compliance, reduces costly recalls and corrective actions, and ultimately delivers safer, more user-friendly devices that better serve clinical needs in practice.  

The Corindus CorPath robotic system represents an advanced technological solution for percutaneous coronary intervention procedures within cardiac catheterization laboratories. This robotic platform enhances precision and control during complex coronary interventions, enabling clinicians to perform minimally invasive cardiac procedures with improved accuracy. The CorPath system demonstrates the growing integration of robotics and automation in interventional cardiology, potentially reducing procedural complications and improving patient outcomes. This innovation reflects the healthcare industry's commitment to leveraging cutting-edge technology to advance cardiac care capabilities and operational efficiency in modern cath labs.

The European Union Medical Device Regulation (MDR), implemented in May 2021, represents a significant overhaul of Europe's medical device regulatory framework, replacing the previous Medical Device Directive. This comprehensive update strengthens patient safety and product transparency by introducing stricter manufacturer requirements, enhanced clinical evidence standards, and rigorous post-market surveillance protocols. The MDR expands device definitions and reinforces clinical oversight to keep pace with technological advancements. These changes substantially impact manufacturers, healthcare professionals, and patients across Europe, requiring stakeholders to adapt their compliance strategies and operational procedures to meet the heightened safety and effectiveness standards now mandated by the regulatory framework.

# Professional Summary Recent advances in cardiovascular implant technology have significantly enhanced device longevity and clinical outcomes. Contemporary developments focus on sophisticated anti-mineralization processes that specifically target calcium-binding phospholipids and aldehyde residues, substantially improving valve durability and performance. These innovations represent a critical evolution in implant design, addressing historical limitations that compromised device longevity. The integration of proprietary bioengineering techniques has enabled manufacturers to develop more resilient materials resistant to calcification and tissue degradation. These improvements translate to extended implant lifespan, reduced revision surgeries, and improved patient outcomes. The field continues advancing through refined material science approaches and targeted chemical modifications, positioning cardiovascular implants as increasingly reliable long-term solutions for patients requiring cardiac intervention.

This prospective, multicenter, observational cohort study aims to establish a post-market registry framework to evaluate the real-world clinical applicability, long-term safety, and effectiveness of innovative heart valve devices in China.

Transcatheter tricuspid valve interventions represent a rapidly evolving field shaped by early clinical experiences and iterative innovation. The formative period of development involved exploratory approaches derived from mitral valve techniques, which yielded important lessons from both successes and setbacks. Early obstacles, such as technical complexity and imaging limitations encountered with direct annuloplasty approaches like the Cardioband system, redirected research efforts and deepened understanding of tricuspid anatomy and physiology. These foundational experiences have informed current therapeutic strategies and established parameters for future innovations. The article examines what has failed, what has proven effective, and emerging approaches in transcatheter tricuspid valve intervention, providing valuable insights for the cardiothoracic surgery community navigating this dynamic treatment landscape.

Robotic-assisted percutaneous coronary intervention represents an emerging advancement in coronary revascularization techniques. This article examines the current evidence and future potential of robotic systems in PCI procedures, comparing them to conventional manual techniques. While manual PCI remains the standard approach for treating coronary artery disease across acute and chronic presentations, robotic-assisted methods offer potential advantages including reduced operator radiation exposure and improved procedural precision. The review discusses applications in various clinical scenarios, from chronic coronary syndromes to acute myocardial infarctions, while emphasizing the importance of individualized patient management strategies and the need for continued investigation into when robotic assistance may provide clinical benefits.

The guidelines are introduced by NMPA Center of Medical Device Evaluation (CMDE). It is not legally binding but highly recommended by regulatory authorities. The revision plan will not only impact the new product registration but also renewals and modifications. It involves type testing, clinical, registration review guidelines, technical guidelines, e.g., Real World Study design, and documentation guidelines, e.g., Indication for Use (IFU) writing. NMPA issues new or updated guidelines throughout the year. Given their importance in understanding what the NMPA reviewers are looking for, it is essential that manufacturers keep up to date with the guidelines that are latest to their specific products. One source to get updates on these guidelines is through our complimentary monthly news roundup that you can opt in from our website www.ChinaMedDevice.com

TruLeaf Medical, Ltd, a fully-owned subsidiary of Allmed Solutions (TASE: ALMD), a clinical-stage medical device company specializing in transcatheter structural heart innovations, is pleased to announce the successful completion of the full two-stage percutaneous heart valve implantation procedure in two additional high-risk patients suffering from severe, refractory heart failure due to leaky tricuspid valve (TR). The first stage of the docking device implantation was performed 3 months ago. In recent days, the second stage of fully percutaneous transcatheter heart valve implantation within the TruLeaf RoseDocdocking station, was successfully performed at a leading medical center in India under a compassionate-use framework. This milestone achievement, conducted in collaboration with a prominent international medical device partner, further validates the clinical utility of TruLeaf Medical RoseDoc  TTVR system for high-risk, no-other-option patients suffering from severe refractory heart failure due to severe TR.

A new multicenter study published in The Annals of Thoracic Surgery finds that reoperative surgical mitral valve replacement (rSMVR) is associated with significantly better long-term survival compared to transcatheter mitral valve-in-valve (mViV) procedures in patients with failing bioprosthetic mitral valves. While both approaches demonstrated similar safety and procedural success at 30 days, key differences emerged over time, particularly beyond the first year.